ELPRO CEO Frederik Dresen was recently featured in Pharmaceutical Commerce discussing how the rapid growth of biologics, cell and gene therapies, and other advanced medicines is reshaping pharmaceutical cold chain requirements.
In the news article, Dresen reflects on the evolution of temperature monitoring over the past four decades, highlighting how the industry has progressed from basic compliance-focused monitoring to more sophisticated approaches centered on risk management, end-to-end quality release assurance, and supply chain resilience.
The conversation also explores how increasingly sensitive therapies are driving demand for greater visibility across global supply chains and why future success will depend on turning data into actionable intelligence through predictive analytics, automation, and faster decision-making.
The feature comes as ELPRO celebrates 40 years of helping life sciences organizations protect product quality and patient safety through trusted monitoring solutions.
To learn more about Dresen’s perspective on the challenges and opportunities shaping the next generation of pharmaceutical cold chain management, read the full article at the link below:
ELPRO CEO on How Biologics Raised the Stakes in Cold Chain Handling | Pharmaceutical Commerce
